MYC and cancer: Based on the in silico prediction models, SPR data and competitive inhibition shown by ELISA, we suggest that rLon and its domains inhibit MYC/MAX complex formation, which would explain the potent inhibition of MYC-dependent gene expression in rLon-treated mice with cancer or infection.